Danil A. Dibrov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Danil A. Dibrov has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Anastasia S. Avdeeva
V.A. Nasonova Research Institute of Rheumatology
7 shared publications - Evgenii L. Nasonov
V.A. Nasonova Research Institute of Rheumatology; N.I. Pirogov Russian National Research Medical University
6 shared publications - Anna Vasilievna Torgashina
V.A. Nasonova Research Institute of Rheumatology
4 shared publications - V. V. Rybakova
V.A. Nasonova Research Institute of Rheumatology
4 shared publications A. S. Avdeeva
Nasonova Research Institute of Rheumatology, Moscow, Russia
3 shared publications- Aleksander M. Lila
V.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation
3 shared publications
Latest Publications
- Open Access
- 13 June 2026
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 98 (5) , 306-313
Immunoglobulin G4-related retroperitoneal fibrosis: clinical, laboratory, imaging, and histopathological features in a Russian single-center cohort
Aim. To describe a Russian cohort of patients with IgG4-related retroperitoneal fibrosis (RPF). Materials and methods. This retrospective single-center study included 36 patients diagnosed with IgG4-related RPF according to the revised 2020 diagnostic criteria. Clinical, laboratory, instrumental, and pathomorphological data were analyzed. Results. The cohort of 36 patients with IgG4-related RPF predominantly comprised males (4:1 ratio), with a median onset age of 52 years and median time to diagnosis of 8 months. The disease most presented with low back or lower abdominal pain (75%), renal dysfunction (44%), elevated serum IgG41.35 g/L (82%), and increased ESR/CRP. Urinary tract infection was detected in 44% due to frequent ureteral catheterization. Isolated retroperitoneal involvement occurred in 72% of cases, with typical infrarenal periaortitis in 58%; atypical sites included perirenal, periureteral, and presacral localizations. Biopsy (n=23) revealed lymphoplasmacytic infiltrate (100%), fibrosis (87%), IgG4+/CD138+40% (71%), with obliterative phlebitis (26%) and tissue eosinophilia (26%) less common. Conclusion. Compared to international data, our findings reveal a higher prevalence of atypical localizations and concomitant urinary tract infections, necessitating their consideration in diagnostic algorithms and treatment planning for RPF patients.
- 13 June 2026
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 98 (5) , 306-313
Open AccessImmunoglobulin G4-related retroperitoneal fibrosis: clinical, laboratory, imaging, and histopathological features in a Russian single-center cohort
Aim. To describe a Russian cohort of patients with IgG4-related retroperitoneal fibrosis (RPF). Materials and methods. This retrospective single-center study included 36 patients diagnosed with IgG4-related RPF according to the revised 2020 diagnostic criteria. Clinical, laboratory, instrumental, and pathomorphological data were analyzed. Results. The cohort of 36 patients with IgG4-related RPF predominantly comprised males (4:1 ratio), with a median onset age of 52 years and median time to diagnosis of 8 months. The disease most presented with low back or lower abdominal pain (75%), renal dysfunction (44%), elevated serum IgG41.35 g/L (82%), and increased ESR/CRP. Urinary tract infection was detected in 44% due to frequent ureteral catheterization. Isolated retroperitoneal involvement occurred in 72% of cases, with typical infrarenal periaortitis in 58%; atypical sites included perirenal, periureteral, and presacral localizations. Biopsy (n=23) revealed lymphoplasmacytic infiltrate (100%), fibrosis (87%), IgG4+/CD138+40% (71%), with obliterative phlebitis (26%) and tissue eosinophilia (26%) less common. Conclusion. Compared to international data, our findings reveal a higher prevalence of atypical localizations and concomitant urinary tract infections, necessitating their consideration in diagnostic algorithms and treatment planning for RPF patients.
- 30 April 2026
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 64 (2)
Aortic involvement in a patient with relapsing polychondritis. Clinical observation
Relapsing polychondritis (RP) is a systemic autoimmune disease characterized by inflammation and destruction of cartilage in various organs. Aortic involvement in RP is relatively rare, occurring in 6.7–9.7% of cases, and is associated with a high risk of mortality (27.3–41.3%) and surgical interventions (65%). Typically, cardiac and aortic involvement in patients with RP is identified approximately five years after the onset of the first symptoms, with 19% of cases being asymptomatic. There are currently no universally accepted standards for screening, diagnosis, and treatment of aortic involvement in RP. We present a clinical case of a patient with RP, aortic involvement, and the development of an aneurysm, who underwent sequential therapy with cyclophosphamide and rituximab. This treatment approach allowed for the control of disease activity and a reduction in glucocorticoid dosage.
- 30 April 2026
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 64 (2)
Aortic involvement in a patient with relapsing polychondritis. Clinical observation
Relapsing polychondritis (RP) is a systemic autoimmune disease characterized by inflammation and destruction of cartilage in various organs. Aortic involvement in RP is relatively rare, occurring in 6.7–9.7% of cases, and is associated with a high risk of mortality (27.3–41.3%) and surgical interventions (65%). Typically, cardiac and aortic involvement in patients with RP is identified approximately five years after the onset of the first symptoms, with 19% of cases being asymptomatic. There are currently no universally accepted standards for screening, diagnosis, and treatment of aortic involvement in RP. We present a clinical case of a patient with RP, aortic involvement, and the development of an aneurysm, who underwent sequential therapy with cyclophosphamide and rituximab. This treatment approach allowed for the control of disease activity and a reduction in glucocorticoid dosage.
- Open Access
- 19 February 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (1) , 29-35
Analysis of changes in peripheral blood B lymphocyte subpopulations in patients with Sjögren’s disease
An altered distribution of peripheral B cells is a marker of B cell hyperactivation in Sjögren’s disease (SjD). Objective: to determine the relationship between the levels of various peripheral blood B lymphocyte subpopulations and the clinical and laboratory manifestations of SjD. Material and methods. The study included 103 patients with SjD (main group) and 31 healthy donors (control group). The diagnosis of SjD was established based on the 2016 ACR/EULAR criteria; all patients underwent a complete clinical and laboratory examination. B lymphocyte subpopulations were analyzed by flow cytometry. The following were assessed: CD19+ B cells, CD19+CD27+ memory B cells, memory B cells with an unswitched immunoglobulin phenotype (“unswitched”, CD19+IgD+CD27+), memory B cells with a switched immunoglobulin phenotype (“switched”, CD19+IgD-CD27+), naive B cells (CD19+IgD+CD27-), double-negative memory B cells (CD19+IgD-CD27-), transitional B cells (CD19+IgD+CD10+CD38+), plasmablasts (CD19+CD38+++IgD-CD27+), and plasma cells (CD19+CD38+). Statistical analysis was performed using GraphPad Prism 8. Results and discussion. Compared with healthy donors, patients with SjD showed a decrease in the number of CD19+ B cells (p=0.0089) and CD27+ memory cells (p=0.018), and an increase in the number of plasmablasts (p16 mg/L) had a higher number of naïve B cells (p=0.0047) and a lower number of “switched” memory cells (p=0.009). Glucocorticoid therapy was associated with a decrease in the number of naive B cells (p=0.0066) and plasmablasts (p=0.0296), but an increase in the number of “switched” memory cells (p=0.0002). In patients with systemic manifestations (vasculitis, interstitial lung disease), an increase in the number of double-negative memory B cells was detected (p=0.028). Conclusion. The obtained data highlight the altered distribution of B-lymphocytes in SjD and their potential for patient stratification and selection of optimal therapy.
- 19 February 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (1) , 29-35
Open AccessAnalysis of changes in peripheral blood B lymphocyte subpopulations in patients with Sjögren’s disease
An altered distribution of peripheral B cells is a marker of B cell hyperactivation in Sjögren’s disease (SjD). Objective: to determine the relationship between the levels of various peripheral blood B lymphocyte subpopulations and the clinical and laboratory manifestations of SjD. Material and methods. The study included 103 patients with SjD (main group) and 31 healthy donors (control group). The diagnosis of SjD was established based on the 2016 ACR/EULAR criteria; all patients underwent a complete clinical and laboratory examination. B lymphocyte subpopulations were analyzed by flow cytometry. The following were assessed: CD19+ B cells, CD19+CD27+ memory B cells, memory B cells with an unswitched immunoglobulin phenotype (“unswitched”, CD19+IgD+CD27+), memory B cells with a switched immunoglobulin phenotype (“switched”, CD19+IgD-CD27+), naive B cells (CD19+IgD+CD27-), double-negative memory B cells (CD19+IgD-CD27-), transitional B cells (CD19+IgD+CD10+CD38+), plasmablasts (CD19+CD38+++IgD-CD27+), and plasma cells (CD19+CD38+). Statistical analysis was performed using GraphPad Prism 8. Results and discussion. Compared with healthy donors, patients with SjD showed a decrease in the number of CD19+ B cells (p=0.0089) and CD27+ memory cells (p=0.018), and an increase in the number of plasmablasts (p16 mg/L) had a higher number of naïve B cells (p=0.0047) and a lower number of “switched” memory cells (p=0.009). Glucocorticoid therapy was associated with a decrease in the number of naive B cells (p=0.0066) and plasmablasts (p=0.0296), but an increase in the number of “switched” memory cells (p=0.0002). In patients with systemic manifestations (vasculitis, interstitial lung disease), an increase in the number of double-negative memory B cells was detected (p=0.028). Conclusion. The obtained data highlight the altered distribution of B-lymphocytes in SjD and their potential for patient stratification and selection of optimal therapy.
- Open Access
- 24 June 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (3) , 7-18
Depletion-restitution therapy of autoimmune rheumatic diseases. Part 2. Perspectives on bispecific antibodies
One of the most promising approaches to depletion-restitution therapy is the development and use of drugs based on bispecific monoclonal antibodies (bsAbs). Therapeutic bsAbs are genetically engineered biological products (biologics) based on immunoglobulin molecules capable of simultaneously binding multiple antigens, making them a promising platform for novel drugs. A specific type of such agent, which incorporates at least two antigen-binding (Fab) fragments within a single immunoglobulin molecule – one targeting a specific cell-surface receptor and the other binding and activating to the CD3ε domain of CD3 molecule of the T-cell receptor complex – has been termed a bispecific T-cell engager (BiTE).Currently, BiTE molecules that engage effector cells of the humoral immune system are the most clinically advanced subclass of bsAbs. Their ability to deplete target cells in peripheral blood and tissues has been clearly demonstrated in the treatment of resistant hematological malignancies such as B-cell precursor acute lymphoblastic leukemia, various lymphoproliferative disorders, and plasma cell dyscrasias. Recent years have seen attempts to repurpose bsAbs for the treatment of refractory, prognostically unfavorable forms of systemic autoimmune rheumatic diseases (SARDs), supported by theoretical rationale, experimental evidence, and parallels with successful CAR-T cell therapy.Beyond BiTEs, the bsAb platform also enables development of biologics with extended pharmacokinetics, multi-cytokine targeting potential for synergistic suppression of inflammation, and checkpoint-directed modulation of targeted cell functional activity.Advantages such as standardized manufacturing, off-the-shelf availability, predictable pharmacokinetics (with a known and limited half-life), flexible dosing regimens enabling slow escalation of the dose, the possibility of individualizing treatment duration and dosing frequency, the feasibility of repeated treatment cycles, the option to discontinue therapy in case of adverse events, and the significantly lower cost of short low-dose treatment cycles compared to CAR-T cell therapy – all these make bsAb-based strategies a highly attractive priority for next-generation depletion-restitution therapies for SARDs.
- 24 June 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (3) , 7-18
Open AccessDepletion-restitution therapy of autoimmune rheumatic diseases. Part 2. Perspectives on bispecific antibodies
One of the most promising approaches to depletion-restitution therapy is the development and use of drugs based on bispecific monoclonal antibodies (bsAbs). Therapeutic bsAbs are genetically engineered biological products (biologics) based on immunoglobulin molecules capable of simultaneously binding multiple antigens, making them a promising platform for novel drugs. A specific type of such agent, which incorporates at least two antigen-binding (Fab) fragments within a single immunoglobulin molecule – one targeting a specific cell-surface receptor and the other binding and activating to the CD3ε domain of CD3 molecule of the T-cell receptor complex – has been termed a bispecific T-cell engager (BiTE).Currently, BiTE molecules that engage effector cells of the humoral immune system are the most clinically advanced subclass of bsAbs. Their ability to deplete target cells in peripheral blood and tissues has been clearly demonstrated in the treatment of resistant hematological malignancies such as B-cell precursor acute lymphoblastic leukemia, various lymphoproliferative disorders, and plasma cell dyscrasias. Recent years have seen attempts to repurpose bsAbs for the treatment of refractory, prognostically unfavorable forms of systemic autoimmune rheumatic diseases (SARDs), supported by theoretical rationale, experimental evidence, and parallels with successful CAR-T cell therapy.Beyond BiTEs, the bsAb platform also enables development of biologics with extended pharmacokinetics, multi-cytokine targeting potential for synergistic suppression of inflammation, and checkpoint-directed modulation of targeted cell functional activity.Advantages such as standardized manufacturing, off-the-shelf availability, predictable pharmacokinetics (with a known and limited half-life), flexible dosing regimens enabling slow escalation of the dose, the possibility of individualizing treatment duration and dosing frequency, the feasibility of repeated treatment cycles, the option to discontinue therapy in case of adverse events, and the significantly lower cost of short low-dose treatment cycles compared to CAR-T cell therapy – all these make bsAb-based strategies a highly attractive priority for next-generation depletion-restitution therapies for SARDs.
- 11 May 2025
- Published by Pleiades Publishing Ltd in Doklady Biochemistry and Biophysics
- Vol. 522 (1) , 352-357
Relation of Cytokine Profile and Antibody Values to Post-Translational Protein Modifications in Patients with Rheumatoid Arthritis (Preliminary Data)
Of the study was to investigate the correlation between cytokine levels and values of antibodies to cyclic citrullinated peptide (ACCP) and antibodies to carbamylated proteins (anti-CarP) in patients with rheumatoid arthritis (RA). . A total of 106 patients with a reliable diagnosis of rheumatoid arthritis were included in the study. Determination of anti-CarP and anti-CCP was performed by enzyme immunoassay. Patients were divided into subgroups depending on the values of ACCP and anti-CarP. The concentration of 27 cytokines in serum was determined using multiplex xMAR technology. . When comparing immunological subgroups, ACCP(+) patients had higher concentrations of IL-1β, IL-1Ra, IL-2, IL-6, IL-8, IL-10, IL-12, IL-13, IL-15, IL-17, FGF, G-CSF, GM-CSF, IFN-γ, IP-10, MCP-1, MIP-1α, TGFb, TNF-α, and VEGF. IL-5, IL-9, eotaxin, MIP-1β, and RANTES values were higher in ACCP(–) patients. In the subgroup of ACCP(–) patients, an inverse correlation between IL-5 and total Sharpe score and between IL-9 and DAS28-CRP was found. In anti-CarP(–) patients (n = 73), higher values of IL-17 were recorded. . Our data support the concept of RA heterogeneity, characterized by the existence of different clinical and immunological subtypes, which may have implications for improving personalised therapy.
- 11 May 2025
- Published by Pleiades Publishing Ltd in Doklady Biochemistry and Biophysics
- Vol. 522 (1) , 352-357
Relation of Cytokine Profile and Antibody Values to Post-Translational Protein Modifications in Patients with Rheumatoid Arthritis (Preliminary Data)
Of the study was to investigate the correlation between cytokine levels and values of antibodies to cyclic citrullinated peptide (ACCP) and antibodies to carbamylated proteins (anti-CarP) in patients with rheumatoid arthritis (RA). . A total of 106 patients with a reliable diagnosis of rheumatoid arthritis were included in the study. Determination of anti-CarP and anti-CCP was performed by enzyme immunoassay. Patients were divided into subgroups depending on the values of ACCP and anti-CarP. The concentration of 27 cytokines in serum was determined using multiplex xMAR technology. . When comparing immunological subgroups, ACCP(+) patients had higher concentrations of IL-1β, IL-1Ra, IL-2, IL-6, IL-8, IL-10, IL-12, IL-13, IL-15, IL-17, FGF, G-CSF, GM-CSF, IFN-γ, IP-10, MCP-1, MIP-1α, TGFb, TNF-α, and VEGF. IL-5, IL-9, eotaxin, MIP-1β, and RANTES values were higher in ACCP(–) patients. In the subgroup of ACCP(–) patients, an inverse correlation between IL-5 and total Sharpe score and between IL-9 and DAS28-CRP was found. In anti-CarP(–) patients (n = 73), higher values of IL-17 were recorded. . Our data support the concept of RA heterogeneity, characterized by the existence of different clinical and immunological subtypes, which may have implications for improving personalised therapy.
- Open Access
- 22 April 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (2) , 7-17
Depletion-restitution therapy for autoimmune rheumatic diseases. Part 1. Fundamental prerequisites and efficacy of modern treatment technologies: anti-B-cell drugs and CAR-T therapy
The key element in the pathogenesis of systemic autoimmune rheumatic diseases is the breakdown of immunological tolerance and the formation of a pool of autoreactive cells. This leads to uncontrolled activation of the effector arm of cellular (T-lymphocytes) and humoral (B-lymphocytes and plasma cells) immunity, proliferation of autoreactive clones, and the formation and persistence of immunological memory cells. In this process, T-cells, B-cells, and plasma cells of immunological memory, in interaction with a complex of pathogenic signals from the microenvironment, ensure the stability and adaptability of the developing inflammatory process.In modern clinical practice, the prevailing approach to prescribing medications is the "therapeutic pyramid" strategy, which involves gradual escalation of treatment until remission is achieved. This approach does not address the mechanisms of immunological tolerance and, as a result, requires lifelong therapy and is associated with numerous adverse effects.The term “depletion-restitution therapy” is proposed (from English “depletion” – exhaustion; and Latin “restitutio ad integrum” – restoration to the original state, complete recovery) to describe an alternative approach. This approach is characterized by methods based on massive, shortterm cytotoxic impact, leading to profound reduction of pathogenic autoreactive cellular clones, followed by repopulation with "naive" cellular elements. Consequently, this restores tolerance mechanisms and enables the formation of ultra-long, drug-free remissions.Currently, the principles of depletion-restitution therapy have already been integrated into oncology, hematology, and neurology. Among the most promising potential targets for such therapy in rheumatology are the effectors of the humoral immune system: B-cells, plasmablasts, and plasma cells. At the present stage, the most promising methods for implementing this approach are CAR-T cells and therapeutic bispecific monoclonal antibodies.
- 22 April 2025
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 19 (2) , 7-17
Open AccessDepletion-restitution therapy for autoimmune rheumatic diseases. Part 1. Fundamental prerequisites and efficacy of modern treatment technologies: anti-B-cell drugs and CAR-T therapy
The key element in the pathogenesis of systemic autoimmune rheumatic diseases is the breakdown of immunological tolerance and the formation of a pool of autoreactive cells. This leads to uncontrolled activation of the effector arm of cellular (T-lymphocytes) and humoral (B-lymphocytes and plasma cells) immunity, proliferation of autoreactive clones, and the formation and persistence of immunological memory cells. In this process, T-cells, B-cells, and plasma cells of immunological memory, in interaction with a complex of pathogenic signals from the microenvironment, ensure the stability and adaptability of the developing inflammatory process.In modern clinical practice, the prevailing approach to prescribing medications is the "therapeutic pyramid" strategy, which involves gradual escalation of treatment until remission is achieved. This approach does not address the mechanisms of immunological tolerance and, as a result, requires lifelong therapy and is associated with numerous adverse effects.The term “depletion-restitution therapy” is proposed (from English “depletion” – exhaustion; and Latin “restitutio ad integrum” – restoration to the original state, complete recovery) to describe an alternative approach. This approach is characterized by methods based on massive, shortterm cytotoxic impact, leading to profound reduction of pathogenic autoreactive cellular clones, followed by repopulation with "naive" cellular elements. Consequently, this restores tolerance mechanisms and enables the formation of ultra-long, drug-free remissions.Currently, the principles of depletion-restitution therapy have already been integrated into oncology, hematology, and neurology. Among the most promising potential targets for such therapy in rheumatology are the effectors of the humoral immune system: B-cells, plasmablasts, and plasma cells. At the present stage, the most promising methods for implementing this approach are CAR-T cells and therapeutic bispecific monoclonal antibodies.
- 13 July 2024
- Published by Pleiades Publishing Ltd in Doklady Biochemistry and Biophysics
- Vol. 517 (1) , 243-249
Clinical Features of ACPA-Negative and ACPA-Positive Variants of Rheumatoid Arthritis
The aim of the study was to investigate the features of the clinical picture of the disease in patients with ACPA–negative and ACPA-positive variants of rheumatoid arthritis. The study included patients with a reliable diagnosis of rheumatoid arthritis (RA) according to the criteria of ACR/EULAR 2010. Depending on the ACPA values, two groups of patients were recruited: ACPA-positive and ACPA-negative, comparable in gender, age, duration of the disease, and therapy. The nature of the onset and course of the disease and the activity of RA were evaluated (according to the DAS28, SDAI, CDAI indices). The study involved 79 patients with ACPA-negative variant of RA and 79 ACPA-positive patients. The age of patients (Me [IR] (in years)) with the ACPA(–) variant was 52 [39; 62]; with the ACPA(+) variant, 54 [42; 62]; the duration of the disease (in months) was 59 [23; 122] and 48 [17; 84], respectively. In ACPA(+) patients, a higher disease activity was determined (by the indices DAS 28crp, DAS28esr, SDAI, CDAI), higher values of C-reactive protein and erythrocyte sedimentation rate, and a greater number of painful and swollen joints (p < 0.05). According to the localization of the involved joints, arthritis of the proximal interphalangeal, metacarpal, wrist and shoulder joints was more often determined in ACPA(+) patients. Systemic manifestations of RA at the time of examination and in the anamnesis were statistically significantly more common in ACPA(+) (32.9%) than in ACPA(–) (17.7%) patients. Of the systemic manifestations, rheumatoid nodules were more common in ACPA(+) patients, whereas a tendency to a higher frequency of neuropathy, sclerites, and episcleritis was revealed in ACPA(–) patients. . In patients with ACPA(–) subtype, clinical signs of joint damage and the inflammatory component are less pronounced compared to ACPA(+). However, the mixed picture of manifestation, the less “bright” course of the disease, the absence of characteristic immunological biomarkers necessitate long-term and careful monitoring of this group of patients. At the same time, the subjective severity of the disease and dysfunction due to ankylosing joints do not differ from the ACPA(+) variant of RA.
- 13 July 2024
- Published by Pleiades Publishing Ltd in Doklady Biochemistry and Biophysics
- Vol. 517 (1) , 243-249
Clinical Features of ACPA-Negative and ACPA-Positive Variants of Rheumatoid Arthritis
The aim of the study was to investigate the features of the clinical picture of the disease in patients with ACPA–negative and ACPA-positive variants of rheumatoid arthritis. The study included patients with a reliable diagnosis of rheumatoid arthritis (RA) according to the criteria of ACR/EULAR 2010. Depending on the ACPA values, two groups of patients were recruited: ACPA-positive and ACPA-negative, comparable in gender, age, duration of the disease, and therapy. The nature of the onset and course of the disease and the activity of RA were evaluated (according to the DAS28, SDAI, CDAI indices). The study involved 79 patients with ACPA-negative variant of RA and 79 ACPA-positive patients. The age of patients (Me [IR] (in years)) with the ACPA(–) variant was 52 [39; 62]; with the ACPA(+) variant, 54 [42; 62]; the duration of the disease (in months) was 59 [23; 122] and 48 [17; 84], respectively. In ACPA(+) patients, a higher disease activity was determined (by the indices DAS 28crp, DAS28esr, SDAI, CDAI), higher values of C-reactive protein and erythrocyte sedimentation rate, and a greater number of painful and swollen joints (p < 0.05). According to the localization of the involved joints, arthritis of the proximal interphalangeal, metacarpal, wrist and shoulder joints was more often determined in ACPA(+) patients. Systemic manifestations of RA at the time of examination and in the anamnesis were statistically significantly more common in ACPA(+) (32.9%) than in ACPA(–) (17.7%) patients. Of the systemic manifestations, rheumatoid nodules were more common in ACPA(+) patients, whereas a tendency to a higher frequency of neuropathy, sclerites, and episcleritis was revealed in ACPA(–) patients. . In patients with ACPA(–) subtype, clinical signs of joint damage and the inflammatory component are less pronounced compared to ACPA(+). However, the mixed picture of manifestation, the less “bright” course of the disease, the absence of characteristic immunological biomarkers necessitate long-term and careful monitoring of this group of patients. At the same time, the subjective severity of the disease and dysfunction due to ankylosing joints do not differ from the ACPA(+) variant of RA.
- 13 July 2024
- Published by Pleiades Publishing Ltd in Doklady Biochemistry and Biophysics
- Vol. 517 (1) , 235-242
Anti-Carbamylated Protein Antibodies in ACPA-Negative and ACPA-Positive Patients with Rheumatoid Arthritis
The objective of this study was to assess the level of antibodies to carbamylated proteins and analyze the clinical and immunological associations in patients with ACPA-negative and ACPA-positive variants of rheumatoid arthritis. . The study involved 150 patients with a reliable diagnosis of rheumatoid arthritis and 25 patients as healthy controls. Depending on ACPA values, two groups of patients were recruited: ACPA-positive (n = 75) and ACPA-negative (n = 75). RA activity was assessed by the DAS28 index. Determination of antibodies to carbamylated proteins was performed by enzyme-linked immunosorbent assay (BlueGene Biotech, China). Quantitative determination of ACPA in serum was performed by enzyme immunoassay using a commercial reagent kit (AxisShield, UK; upper limit of normal 5.0 U/mL; Orgentec, Germany; upper limit of normal 20.0 U/mL). . Median anti-CarP in patients with RA was 126.2 [100.83; 157.41] ng/mL and was statistically significantly higher (p < 0.001) than in healthy controls (88.89 [70.53; 107.75] ng/mL). Among all patients with RA, 50 (33.3%) were anti-Carp-positive (22 (29.3%) in the ACPA(+) group and 28 (37.3%) in the ACPA(–) group), and one (2%) volunteer from healthy controls was anti-CarP(+) (p = 0.002). In ROC analysis performed to assess the diagnostic significance of anti-CarP for RA for all patients with RA, the area under the curve was 0.783 ± 0.047 with 95% CI: 0.691–0.874 (p < 0.001), with a cut-off point of 143 ng/mL, specificity 96%, sensitivity 36.7%. In the ACPA(+) RA group, the erosion count was statistically significantly higher (p = 0.044) in anti-CarP(+) patients than in anti-CarP(–) patients. A weak direct correlation between anti-CarP and DAS28 was found in the ACPA(–) RA group. . We studied the predictive value of anti-CarP as an auxiliary biomarker in ACPA(+) and ACPA(–) subtypes of RA. ACPA(+) anti-CarP(+) patients have a more “erosive” subtype of the disease than ACPA(+) anti-CarP(–) patients. In ACPA(–) patients, anti-CarP helps to identify a more erosive subtype of the disease, and among ACPA(–) patients it helps to reduce the proportion of seronegative patients. Further studies are required to determine the optimal standards for the laboratory diagnosis of anti-CarP and to clarify the diagnostic potential of these ABs as part of the differential diagnosis of arthritis in other rheumatic diseases.
- 13 July 2024
- Published by Pleiades Publishing Ltd in Doklady Biochemistry and Biophysics
- Vol. 517 (1) , 235-242
Anti-Carbamylated Protein Antibodies in ACPA-Negative and ACPA-Positive Patients with Rheumatoid Arthritis
The objective of this study was to assess the level of antibodies to carbamylated proteins and analyze the clinical and immunological associations in patients with ACPA-negative and ACPA-positive variants of rheumatoid arthritis. . The study involved 150 patients with a reliable diagnosis of rheumatoid arthritis and 25 patients as healthy controls. Depending on ACPA values, two groups of patients were recruited: ACPA-positive (n = 75) and ACPA-negative (n = 75). RA activity was assessed by the DAS28 index. Determination of antibodies to carbamylated proteins was performed by enzyme-linked immunosorbent assay (BlueGene Biotech, China). Quantitative determination of ACPA in serum was performed by enzyme immunoassay using a commercial reagent kit (AxisShield, UK; upper limit of normal 5.0 U/mL; Orgentec, Germany; upper limit of normal 20.0 U/mL). . Median anti-CarP in patients with RA was 126.2 [100.83; 157.41] ng/mL and was statistically significantly higher (p < 0.001) than in healthy controls (88.89 [70.53; 107.75] ng/mL). Among all patients with RA, 50 (33.3%) were anti-Carp-positive (22 (29.3%) in the ACPA(+) group and 28 (37.3%) in the ACPA(–) group), and one (2%) volunteer from healthy controls was anti-CarP(+) (p = 0.002). In ROC analysis performed to assess the diagnostic significance of anti-CarP for RA for all patients with RA, the area under the curve was 0.783 ± 0.047 with 95% CI: 0.691–0.874 (p < 0.001), with a cut-off point of 143 ng/mL, specificity 96%, sensitivity 36.7%. In the ACPA(+) RA group, the erosion count was statistically significantly higher (p = 0.044) in anti-CarP(+) patients than in anti-CarP(–) patients. A weak direct correlation between anti-CarP and DAS28 was found in the ACPA(–) RA group. . We studied the predictive value of anti-CarP as an auxiliary biomarker in ACPA(+) and ACPA(–) subtypes of RA. ACPA(+) anti-CarP(+) patients have a more “erosive” subtype of the disease than ACPA(+) anti-CarP(–) patients. In ACPA(–) patients, anti-CarP helps to identify a more erosive subtype of the disease, and among ACPA(–) patients it helps to reduce the proportion of seronegative patients. Further studies are required to determine the optimal standards for the laboratory diagnosis of anti-CarP and to clarify the diagnostic potential of these ABs as part of the differential diagnosis of arthritis in other rheumatic diseases.
- 25 June 2024
- Published by I.N. Ulianov Chuvash State University in Acta medica Eurasica
- No. 2
RELAPSING POLYCHONDRITIS: PROBLEMS AND SOLUTIONS
The purpose of this study is to evaluate the clinical course and effectiveness of pharmacological therapy in a patient with recurrent polychondritis. Material and methods. Retrospective and prospective analyses of the diagnosis, course and treatment of recurrent polychondritis in the patient were performed. The patient was diagnosed based on the McAdam classification criteria. The patient was assigned laboratory tests: general, biochemical and immunological blood analyses; instrumental methods: X-ray and ultrasound examinations of the vessels, spirometry. The results of the study. The patient was first diagnosed with recurrent polychondritis at the age of 58. The patient complained of pain, swelling and hyperemia of the auricles, a change in the shape of the nose; attacks of suffocation, which were stopped by inhalations of salbutamol, hoarseness of voice; prolonged subfebrility (37.5–38°C), arthralgia. In September 2022, he was examined by an otolaryngologist, then sent to a rheumatologist to determine therapeutic and diagnostic tactics. According to the results of laboratory data: erythrocyte sedimentation rate – 48 mm/hour, C-reactive protein – 30.1 mg/l, rheumatoid factor – 10 units/l, antibodies to cyclic citrulline peptide- 7.0 units, the result of immunoblot is negative; antibodies to myeloperoxidase – 4.15 RU/ml, antibodies to proteinase – 32.2 RU/ml. During spirometry, there was a violation of the function of external respiration of an obstructive type. Ultrasound of the joints: signs of synovitis of the proximal interphalangeal joints of both hands. Based on the McAdam classification criteria, a clinical diagnosis was made: recurrent polychondritis with systemic manifestations: chondritis of the auricles and nasal congestion, seronegative arthritis, bronchoobstructive syndrome, constitutional symptom (fever). The patient was prescribed therapy: prednisone 20 mg/day, methotrexate 25 mg/week. Clinical and laboratory remission was achieved, but subsequently relapses of the disease and the appearance of a herpes infection were observed (antiviral therapy was prescribed). In July 2023, he was sent for examination and treatment at the Nasonova Research Institute of Rheumatology. The patient was submitted to the commission on therapy with genetically engineered biological drugs. Taking into account the often recurrent herpetic infection, the appointment of genetically engineered biological drugs was postponed. It is recommended to continue taking prednisolone at a dose of 20 mg/day, antiviral therapy (valciclovir). Dapsone 100 mg per day was added to the treatment, but his patient independently canceled the drug due to the appearance of severe nausea and insomnia. Subsequently, a rheumatologist with an immunosuppressive purpose prescribed azathiroprine 150 mg/day, continued taking prednisone 20 mg/day, however, exacerbations of the disease were registered. The lack of effect of the therapy was the basis for the patient's re-hospitalization at the V.A. Nasonova Research Institute of Rheumatology. Conclusions. Recurrent polychondritis is a rapidly progressive disease, and in the absence of timely diagnosis and treatment, it has a risk of developing life-threatening conditions.
- 25 June 2024
- Published by I.N. Ulianov Chuvash State University in Acta medica Eurasica
- No. 2
RELAPSING POLYCHONDRITIS: PROBLEMS AND SOLUTIONS
The purpose of this study is to evaluate the clinical course and effectiveness of pharmacological therapy in a patient with recurrent polychondritis. Material and methods. Retrospective and prospective analyses of the diagnosis, course and treatment of recurrent polychondritis in the patient were performed. The patient was diagnosed based on the McAdam classification criteria. The patient was assigned laboratory tests: general, biochemical and immunological blood analyses; instrumental methods: X-ray and ultrasound examinations of the vessels, spirometry. The results of the study. The patient was first diagnosed with recurrent polychondritis at the age of 58. The patient complained of pain, swelling and hyperemia of the auricles, a change in the shape of the nose; attacks of suffocation, which were stopped by inhalations of salbutamol, hoarseness of voice; prolonged subfebrility (37.5–38°C), arthralgia. In September 2022, he was examined by an otolaryngologist, then sent to a rheumatologist to determine therapeutic and diagnostic tactics. According to the results of laboratory data: erythrocyte sedimentation rate – 48 mm/hour, C-reactive protein – 30.1 mg/l, rheumatoid factor – 10 units/l, antibodies to cyclic citrulline peptide- 7.0 units, the result of immunoblot is negative; antibodies to myeloperoxidase – 4.15 RU/ml, antibodies to proteinase – 32.2 RU/ml. During spirometry, there was a violation of the function of external respiration of an obstructive type. Ultrasound of the joints: signs of synovitis of the proximal interphalangeal joints of both hands. Based on the McAdam classification criteria, a clinical diagnosis was made: recurrent polychondritis with systemic manifestations: chondritis of the auricles and nasal congestion, seronegative arthritis, bronchoobstructive syndrome, constitutional symptom (fever). The patient was prescribed therapy: prednisone 20 mg/day, methotrexate 25 mg/week. Clinical and laboratory remission was achieved, but subsequently relapses of the disease and the appearance of a herpes infection were observed (antiviral therapy was prescribed). In July 2023, he was sent for examination and treatment at the Nasonova Research Institute of Rheumatology. The patient was submitted to the commission on therapy with genetically engineered biological drugs. Taking into account the often recurrent herpetic infection, the appointment of genetically engineered biological drugs was postponed. It is recommended to continue taking prednisolone at a dose of 20 mg/day, antiviral therapy (valciclovir). Dapsone 100 mg per day was added to the treatment, but his patient independently canceled the drug due to the appearance of severe nausea and insomnia. Subsequently, a rheumatologist with an immunosuppressive purpose prescribed azathiroprine 150 mg/day, continued taking prednisone 20 mg/day, however, exacerbations of the disease were registered. The lack of effect of the therapy was the basis for the patient's re-hospitalization at the V.A. Nasonova Research Institute of Rheumatology. Conclusions. Recurrent polychondritis is a rapidly progressive disease, and in the absence of timely diagnosis and treatment, it has a risk of developing life-threatening conditions.
- Open Access
- 28 April 2024
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 62 (2) , 186-191
Relation of cytokine profile and antibody values to post-translational protein modifications in patients with rheumatoid arthritis (preliminary data)
The aim of the study was to investigate the relationship between cytokine levels and values of antibodies to cyclic citrullinated peptide (anti-CCP) and antibodies to carbamylated proteins (anti-CarP) in patients with rheumatoid arthritis (RA). Materials and methods. 106 patients with a reliable diagnosis of rheumatoid arthritis were included in the study. Determination of anti-CarP and anti-CCP was performed by enzyme immunoassay. Patients were divided into subgroups depending on the values of anti-CCP and anti-CarP. The concentration of 27 cytokines in serum was determined using multiplex xMAR technology. Results and discussion. When comparing immunological subgroups, anti-CCP(+) patients had higher concentrations of interleukin (IL) 1β, IL-1Ra, IL-2, IL-6, IL-8, IL-10, IL-12, IL-13, IL-15, IL-17, fibroblast growth factor, granulocyte colony-stimulating factor (CSF), granulocyte-macrophage CSF, interferon (IFN) γ, IFN0γ-induced protein 10, monocyte chemoattractant protein 1, macrophage inflammatory protein 1α (MIP-1α), transforming growth factor bb, tumor necrosis factor α and vascular endothelial growth factor. IL-5, IL-9, eotaxin, MIP-1β and RANTES (regulated on activation, normal T cell expressed and secreted) values were higher in anti-CCP(–) patients. In the subgroup of anti-CCP(–) patients, an inverse correlation was found between IL-5 and total Sharpe score, between IL-9 and DAS28-CRP (Disease Activity Score with C-reactive protein calculation). In anti-Carp(–) patients (n=73) higher values of IL-17 were recorded. Conclusion. Our data support the concept of RA heterogeneity, characterised by the existence of different clinical and immunological subtypes, which may have implications for improving personalised therapy.
- 28 April 2024
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 62 (2) , 186-191
Open AccessRelation of cytokine profile and antibody values to post-translational protein modifications in patients with rheumatoid arthritis (preliminary data)
The aim of the study was to investigate the relationship between cytokine levels and values of antibodies to cyclic citrullinated peptide (anti-CCP) and antibodies to carbamylated proteins (anti-CarP) in patients with rheumatoid arthritis (RA). Materials and methods. 106 patients with a reliable diagnosis of rheumatoid arthritis were included in the study. Determination of anti-CarP and anti-CCP was performed by enzyme immunoassay. Patients were divided into subgroups depending on the values of anti-CCP and anti-CarP. The concentration of 27 cytokines in serum was determined using multiplex xMAR technology. Results and discussion. When comparing immunological subgroups, anti-CCP(+) patients had higher concentrations of interleukin (IL) 1β, IL-1Ra, IL-2, IL-6, IL-8, IL-10, IL-12, IL-13, IL-15, IL-17, fibroblast growth factor, granulocyte colony-stimulating factor (CSF), granulocyte-macrophage CSF, interferon (IFN) γ, IFN0γ-induced protein 10, monocyte chemoattractant protein 1, macrophage inflammatory protein 1α (MIP-1α), transforming growth factor bb, tumor necrosis factor α and vascular endothelial growth factor. IL-5, IL-9, eotaxin, MIP-1β and RANTES (regulated on activation, normal T cell expressed and secreted) values were higher in anti-CCP(–) patients. In the subgroup of anti-CCP(–) patients, an inverse correlation was found between IL-5 and total Sharpe score, between IL-9 and DAS28-CRP (Disease Activity Score with C-reactive protein calculation). In anti-Carp(–) patients (n=73) higher values of IL-17 were recorded. Conclusion. Our data support the concept of RA heterogeneity, characterised by the existence of different clinical and immunological subtypes, which may have implications for improving personalised therapy.